Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C
Data up to Jan 2025
Total Citations Per Year
Abstract
References (9)
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
2002 • 6,505 citations
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
2001 • 6,133 citations
Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C
2004 • 2,888 citations
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
2003 • 907 citations
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
2004 • 338 citations
Future therapy of hepatitis C
2002 • 88 citations
Sensitivity of NS3 Serine Proteases from Hepatitis C Virus Genotypes 2 and 3 to the Inhibitor BILN 2061
2004 • 85 citations
Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003
2004 • 63 citations
Future therapy of hepatitis C
2002 • 48 citations
Cited By (0)
No citing papers found in database